image
Healthcare - Medical - Care Facilities - NYSE - US
$ 8.43
0.717 %
$ 424 M
Market Cap
-3.62
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one EHAB stock under the worst case scenario is HIDDEN Compared to the current market price of 8.43 USD, Enhabit, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one EHAB stock under the base case scenario is HIDDEN Compared to the current market price of 8.43 USD, Enhabit, Inc. is HIDDEN

This DCF valuation model was last updated on Mar, 2, 2025.

The intrinsic value of one EHAB stock under the best case scenario is HIDDEN Compared to the current market price of 8.43 USD, Enhabit, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
1.05 B REVENUE
-3.40%
-47.6 M OPERATING INCOME
-44.24%
-80.5 M NET INCOME
-124.61%
48.4 M OPERATING CASH FLOW
-39.58%
-5.3 M INVESTING CASH FLOW
87.47%
-40.5 M FINANCING CASH FLOW
-117.74%
254 M REVENUE
-2.69%
-98 M OPERATING INCOME
-875.00%
-110 M NET INCOME
-54650.00%
28.4 M OPERATING CASH FLOW
195.83%
-400 K INVESTING CASH FLOW
33.33%
-10.8 M FINANCING CASH FLOW
40.66%
Balance Sheet Enhabit, Inc.
image
Current Assets 210 M
Cash & Short-Term Investments 27.4 M
Receivables 168 M
Other Current Assets 15 M
Non-Current Assets 1.22 B
Long-Term Investments 0
PP&E 76.5 M
Other Non-Current Assets 1.15 B
Current Liabilities 138 M
Accounts Payable 7.6 M
Short-Term Debt 34.3 M
Other Current Liabilities 95.8 M
Non-Current Liabilities 594 M
Long-Term Debt 573 M
Other Non-Current Liabilities 21.5 M
EFFICIENCY
Earnings Waterfall Enhabit, Inc.
image
Revenue 1.05 B
Cost Of Revenue 536 M
Gross Profit 511 M
Operating Expenses 558 M
Operating Income -47.6 M
Other Expenses 32.9 M
Net Income -80.5 M
RATIOS
48.81% GROSS MARGIN
48.81%
-4.55% OPERATING MARGIN
-4.55%
-7.69% NET MARGIN
-7.69%
-12.02% ROE
-12.02%
-5.62% ROA
-5.62%
-3.13% ROIC
-3.13%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Enhabit, Inc.
image
Net Income -80.5 M
Depreciation & Amortization 30.9 M
Capital Expenditures -3.5 M
Stock-Based Compensation 8.9 M
Change in Working Capital 11.7 M
Others 112 M
Free Cash Flow 44.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Enhabit, Inc.
image
Wall Street analysts predict an average 1-year price target for EHAB of $9.6 , with forecasts ranging from a low of $8.5 to a high of $12 .
EHAB Lowest Price Target Wall Street Target
8.5 USD 0.83%
EHAB Average Price Target Wall Street Target
9.6 USD 13.88%
EHAB Highest Price Target Wall Street Target
12 USD 42.35%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Enhabit, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
5.59 K USD 1
Bought
167 K USD 2
0-3 MONTHS
77.2 K USD 1
3-6 MONTHS
98.7 K USD 1
6-9 MONTHS
184 K USD 2
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Dec 12, 2024
Bought 34.8 K USD
Bolton Jeffrey
Director
+ 4000
8.69 USD
2 months ago
Dec 10, 2024
Bought 132 K USD
MCGUIGAN STUART M
Director
+ 15000
8.81 USD
3 months ago
Nov 12, 2024
Bought 22.8 K USD
Bolton Jeffrey
Director
+ 3000
7.6 USD
3 months ago
Nov 08, 2024
Bought 49.3 K USD
Bolton Jeffrey
Director
+ 6351
7.77 USD
3 months ago
Nov 08, 2024
Bought 5.03 K USD
Bolton Jeffrey
Director
+ 649
7.75 USD
6 months ago
Aug 22, 2024
Bought 40 K USD
Bolton Jeffrey
Director
+ 5000
8.01 USD
6 months ago
Aug 09, 2024
Bought 41.4 K USD
Bolton Jeffrey
Director
+ 5000
8.29 USD
6 months ago
Aug 08, 2024
Bought 17.2 K USD
Bolton Jeffrey
Director
+ 2000
8.6 USD
9 months ago
May 17, 2024
Bought 83.3 K USD
Bolton Jeffrey
Director
+ 10000
8.33 USD
9 months ago
May 14, 2024
Bought 18 K USD
Hoeflinger Erin
Director
+ 2000
9 USD
9 months ago
May 10, 2024
Bought 82.4 K USD
Bolton Jeffrey
Director
+ 10000
8.24 USD
1 year ago
Mar 01, 2024
Sell 5.59 K USD
Langham Ronald Leroy JR
EVP Clinical Excel. & Strategy
- 634
8.81 USD
1 year ago
May 26, 2023
Bought 23.2 K USD
Bolton Jeffrey
Director
+ 2000
11.61 USD
1 year ago
May 22, 2023
Bought 120 K USD
SHAW L EDWARD JR
Director
+ 10000
11.98 USD
1 year ago
May 18, 2023
Bought 24.8 K USD
Hoeflinger Erin
Director
+ 2100
11.82 USD
1 year ago
May 18, 2023
Bought 120 K USD
Langham Ronald Leroy JR
EVP Clinical Excel. & Strategy
+ 10000
11.99 USD
1 year ago
May 17, 2023
Bought 23.6 K USD
Bolton Jeffrey
Director
+ 2000
11.8 USD
2 years ago
Nov 18, 2022
Bought 12.7 K USD
Bolton Jeffrey
Director
+ 1000
12.69 USD
2 years ago
Nov 09, 2022
Bought 25.5 K USD
Bolton Jeffrey
Director
+ 2000
12.75 USD
2 years ago
Nov 08, 2022
Bought 25.8 K USD
Bolton Jeffrey
Director
+ 2000
12.89 USD
2 years ago
Nov 08, 2022
Bought 5.78 K USD
HIGDON LEO I JR
Director
+ 426
13.57 USD
2 years ago
Nov 07, 2022
Bought 105 K USD
Rush Gregory S
Director
+ 8300
12.69 USD
2 years ago
Nov 04, 2022
Bought 21.4 K USD
Rush Gregory S
Director
+ 1700
12.58 USD
2 years ago
Aug 31, 2022
Bought 24.8 K USD
Brown-Stevenson Tina L.
director:
+ 1550
15.99 USD
2 years ago
Aug 18, 2022
Bought 13.5 K USD
Hoeflinger Erin
director:
+ 970
13.9 USD
2 years ago
Aug 18, 2022
Bought 82.1 K USD
Hoeflinger Erin
Director
+ 6030
13.62 USD
2 years ago
Aug 17, 2022
Bought 25 K USD
Marion Tanya Renee
Chief Human Resources Officer
+ 1712
14.6 USD
2 years ago
Aug 11, 2022
Bought 50.1 K USD
ELSON CHARLES M
director:
+ 3700
13.55 USD
2 years ago
Aug 08, 2022
Bought 13.6 K USD
MAUPIN JOHN E JR D D S
director:
+ 1000
13.59 USD
2 years ago
Aug 08, 2022
Bought 20.6 K USD
CURL YVONNE M
director:
+ 1500
13.75 USD
2 years ago
Aug 09, 2022
Bought 413 K USD
Jacobsmeyer Barbara Ann
President and CEO
+ 30000
13.78 USD
2 years ago
Aug 09, 2022
Bought 136 K USD
SHAW L EDWARD JR
director:
+ 10000
13.64 USD
2 years ago
Aug 04, 2022
Bought 37.1 K USD
HIGDON LEO I JR
director:
+ 3000
12.37 USD
2 years ago
Aug 04, 2022
Bought 176 K USD
LaMonica Susan
director:
+ 15000
11.72 USD
2 years ago
Aug 04, 2022
Bought 11.7 K USD
Bolton Jeffrey
director:
+ 1000
11.74 USD
2 years ago
Aug 03, 2022
Bought 61.1 K USD
HIGDON LEO I JR
director:
+ 4500
13.57 USD
7. News
Enhabit (EHAB) Is Attractively Priced Despite Fast-paced Momentum Enhabit (EHAB) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices. zacks.com - 1 week ago
Enhabit Home Health & Hospice Announces Date of 2024 Fourth Quarter Earnings Call DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its results for the fourth quarter ended Dec. 31, 2024, on March 5, 2025, and host a webcast and conference call on March 6, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time. March 6, 2025 10 a.m. EDT Toll-free: 888-660-6150 International: 929-203-0843 Conference ID: 5248158 I. businesswire.com - 2 weeks ago
Enhabit: Healthcare Predictive Analytics, FCF, Very Undervalued EHAB's investments in healthcare predictive analytics, expected to grow at 23%-24% CAGR, could significantly boost future net income growth. Restructuring, activism, and strategic reviews are potential catalysts for stock price appreciation, enhancing financial flexibility from 2025 to 2030. Despite recent negative net income, EHAB's consistent positive cash flow and undervaluation indicate substantial upside potential in stock price. seekingalpha.com - 3 weeks ago
Enhabit Home Health & Hospice Earns 2025 Great Place To Work Certification™ DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice provider, announced today that it is proud to be Certified™ by Great Place To Work®. This prestigious award is based entirely on the experiences of current employees working at Enhabit. This year, 83% of employees said it's a great place to work, which is 26 points higher than the average U.S. company. Great Place To Work® is the global authority on workplace culture, employee experience and leadership behavi. businesswire.com - 1 month ago
Enhabit (EHAB) Shows Fast-paced Momentum But Is Still a Bargain Stock If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. zacks.com - 1 month ago
Delaware Court of Chancery Awards Damages and Other Relief to Encompass Health and Enhabit for Misconduct by April Anthony, Other Former Officers, and Private Equity Firms Vistria Group and Nautic Partners BIRMINGHAM, Ala., and DALLAS , Dec. 4, 2024 /PRNewswire/ -- On Monday, Encompass Health and Enhabit won their lawsuit in the Delaware Court of Chancery related to breaches of fiduciary duty by April Anthony, Luke James, and Chris Walker while they served as the senior officers at Encompass Health's former home health and hospice division, which is now Enhabit. prnewswire.com - 2 months ago
Delaware Court of Chancery Awards Damages and Other Relief to Encompass Health and Enhabit for Misconduct by April Anthony, Other Former Officers, and Private Equity Firms Vistria Group and Nautic Partners BIRMINGHAM, Ala. & DALLAS--(BUSINESS WIRE)--On Monday, Encompass Health and Enhabit won their lawsuit in the Delaware Court of Chancery related to breaches of fiduciary duty by April Anthony, Luke James, and Chris Walker while they served as the senior officers at Encompass Health's former home health and hospice division, which is now Enhabit. The Court awarded judgment against private equity firms Vistria Group and Nautic Partners and the home health and hospice business now known as VitalCar. businesswire.com - 2 months ago
Enhabit Announces Participation in Upcoming BofA Home Care Conference DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice provider, today announced its participation in the upcoming BofA Securities 2024 Home Care Conference. Enhabit's President and Chief Executive Officer Barb Jacobsmeyer, incoming Chief Financial Officer Ryan Solomon, and Senior Vice President of Strategic Finance & Treasurer Jobie Williams will participate in a fireside chat on Tuesday, Dec. 10, at 9:00 a.m. EST. The fireside chat will be webcast live and. businesswire.com - 3 months ago
Enhabit, Inc. (EHAB) Q3 2024 Earnings Call Transcript Enhabit, Inc. (NYSE:EHAB ) Q3 2024 Earnings Conference Call November 7, 2024 10:00 AM ET Company Participants Jobie Williams – Senior Vice President and Treasurer Barb Jacobsmeyer – President and Chief Executive Officer Crissy Carlisle – Chief Financial Officer Conference Call Participants Brian Tanquilut – Jefferies A. J. Rice – UBS Ryan Langston – TD Cowen Operator Good morning, everyone and welcome to Enhabit's Home Health and Hospice's Third Quarter, 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
Enhabit Home Health & Hospice Appoints Ryan Solomon as Chief Financial Officer DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), (“Enhabit”), a leading home health and hospice provider, today announced the appointment of Ryan Solomon as its next chief financial officer (CFO), effective Dec. 9, 2024. Mr. Solomon's appointment follows the previously announced transition of Crissy Carlisle, CFO. Mr. Solomon brings to Enhabit over 20 years of corporate strategy and finance experience, including eight years as CFO in the home health and hospice space and other industries. M. businesswire.com - 3 months ago
Enhabit (EHAB) Misses Q3 Earnings and Revenue Estimates Enhabit (EHAB) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago. zacks.com - 3 months ago
Enhabit Reports Third Quarter 2024 Financial Results DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the third quarter ended September 30, 2024. “Our continued progress in our strategies during the third quarter resulted in Adjusted EBITDA growth year over year and strong free cash flow generation that led to further debt reduction,” said Enhabit's President and Chief Executive Officer Barb Jacobsmeyer. “The payor innovation strategy continues to fo. businesswire.com - 3 months ago
8. Profile Summary

Enhabit, Inc. EHAB

image
COUNTRY US
INDUSTRY Medical - Care Facilities
MARKET CAP $ 424 M
Dividend Yield 0.00%
Description Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
Contact 6688 N. Central Expressway, Dallas, TX, 75206 https://www.ehab.com
IPO Date June 23, 2022
Employees 10800
Officers Ms. Julie Diane Jolley B.S.N., R.N. Executive Vice President of Home Health Ms. Jeanne Kalvaitis B.S.N., R.N. Executive Vice President of Hospice Operations Mr. Dylan C. Black General Counsel & Secretary Mr. Ronald L. Langham Jr., M.B.A., P.T. Executive Vice President of Clinical Excellence & Strategy Ms. Barbara Ann Jacobsmeyer B.S., M.A., P.T. President, Chief Executive Officer & Director Ms. Tanya R. Marion Chief Human Resources Officer Mr. Ryan Solomon Chief Financial Officer